Loading...

Fady Malik, MD, PhD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address505 Parnassus Avenue
San Francisco CA 94117
Phone415-353-3817
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San Francisco Clinical Fellowship School of Medicine
    University of California, San Francisco Residency School of Medicine
    University of California, San FranciscoM.D.1994 Medicine
    University of California, San FranciscoPh.D.1993 Graduate Division (Neuroscience)

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Acute and chronic tirasemtiv treatment improves in vivo and in vitro muscle performance in actin-based nemaline myopathy mice. Hum Mol Genet. 2021 Apr 28. de Winter JM, Gineste C, Minardi E, Brocca L, Rossi M, Borsboom T, Beggs AH, Bernard M, Bendahan D, Hwee DT, Malik FI, Pellegrino MA, Bottinelli R, Gondin J, Ottenheijm CAC. PMID: 33909041.
      View in: PubMed   Mentions:    Fields:    
    2. Effect of Ejection Fraction on Clinical Outcomes in Patients treated with Omecamtiv Mecarbil in GALACTIC-HF. J Am Coll Cardiol. 2021 Apr 28. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Biering-Sørensen T, Böhm M, Bonderman D, Fang JC, Lanfear DE, Lund M, Momomura SI, O'Meara E, Ponikowski P, Spinar J, Flores-Arredondo JH, Claggett BL, Heitner SB, Kupfer S, Abbasi SA, Malik FI, GALACTIC-HF Investigators . PMID: 34015475.
      View in: PubMed   Mentions:    Fields:    
    3. The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Right Ventricular Structure and Function in Chronic Systolic Heart Failure (COSMIC -HF). Eur J Heart Fail. 2021 Apr 07. Sørensen TB, Minamisawa M, Liu J, Claggett B, Papolos AI, Felker GM, McMurray JJV, Legg JC, Malik FI, Honarpour N, Kurtz CE, Teerlink JR, Solomon SD. PMID: 33826209.
      View in: PubMed   Mentions:    Fields:    
    4. Noninvasive ventilation use by patients enrolled in VITALITY-ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2021 Apr 01; 1-9. Rudnicki SA, Andrews JA, Bian A, Cockroft BM, Cudkowicz ME, Hardiman O, Malik FI, Meng L, Wolff AA, Shefner JM, VITALITY-ALS STUDY GROUP . PMID: 33792451.
      View in: PubMed   Mentions:    Fields:    
    5. Pathogenic variants in TNNC2 cause congenital myopathy due to an impaired force response to calcium. J Clin Invest. 2021 Mar 23. van de Locht M, Donkervoort S, de Winter JM, Conijn S, Begthel L, Kusters B, Mohassel P, Hu Y, Medne L, Quinn C, Moore SA, Foley AR, Seo G, Hwee DT, Malik FI, Irving T, Ma W, Granzier H, Kamsteeg EJ, Immadisetty K, Kekenes-Huskey P, Pinto JR, Voermans N, Bönnemann CG, Ottenheijm CA. PMID: 33755597.
      View in: PubMed   Mentions:    Fields:    
    6. Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study. Neurotherapeutics. 2021 Feb 23. Rudnicki SA, Andrews JA, Duong T, Cockroft BM, Malik FI, Meng L, Wei J, Wolff AA, Genge A, Johnson NE, Tesi-Rocha C, Connolly AM, Darras BT, Felice K, Shieh PB, Mah JK, Statland J, Campbell C, Habib AA, Kuntz NL, Oskoui M, Day JW. PMID: 33624184.
      View in: PubMed   Mentions:    Fields:    
    7. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. N Engl J Med. 2021 01 14; 384(2):105-116. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T, Böhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlström U, Echeverria LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Li J, Lund M, Macdonald P, Mareev V, Momomura SI, O'Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Varin C, Honarpour N, Abbasi SA, Malik FI, Kurtz CE. PMID: 33185990.
      View in: PubMed   Mentions: 5     Fields:    
    8. Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients with Chronic Heart Failure: Results from the COSMIC-HF Study. Circ Heart Fail. 2020 Nov 12. Felker GM, Solomon SD, McMurray JJV, Cleland JGF, Abbasi SA, Malik FI, Zhang H, Globe G, Teerlink JR. PMID: 33176437.
      View in: PubMed   Mentions:    Fields:    
    9. Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure: The COSMIC-HF Trial. Circ Heart Fail. 2020 Dec; 13(12):e008007. Biering-Sørensen T, Minamisawa M, Claggett B, Liu J, Felker GM, McMurray JJV, Malik FI, Abbasi S, Kurtz CE, Teerlink JR, Solomon SD. PMID: 33176443.
      View in: PubMed   Mentions:    Fields:    
    10. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. Eur J Heart Fail. 2020 Nov; 22(11):2160-2171. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T, Böhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlström U, Echeverria Correa LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Lund M, Macdonald P, Mareev V, Momomura SI, O'Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Abbasi SA, Varin C, Malik FI, Kurtz CE, . PMID: 32985088.
      View in: PubMed   Mentions:    Fields:    
    11. Left ventricular systolic ejection time is an independent predictor of all-cause mortality in heart failure with reduced ejection fraction. Eur J Heart Fail. 2020 Oct 09. Alhakak AS, Sengeløv M, Jørgensen PG, Bruun NE, Johnsen C, Abildgaard U, Iversen AZ, Hansen TF, Teerlink JR, Malik FI, Solomon SD, Gislason G, Biering-Sørensen T. PMID: 33034122.
      View in: PubMed   Mentions:    Fields:    
    12. A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2020 Sep 24; 1-13. Shefner JM, Andrews JA, Genge A, Jackson C, Lechtzin N, Miller TM, Cockroft BM, Meng L, Wei J, Wolff AA, Malik FI, Bodkin C, Brooks BR, Caress J, Dionne A, Fee D, Goutman SA, Goyal NA, Hardiman O, Hayat G, Heiman-Patterson T, Heitzman D, Henderson RD, Johnston W, Karam C, Kiernan MC, Kolb SJ, Korngut L, Ladha S, Matte G, Mora JS, Needham M, Oskarsson B, Pattee GL, Pioro EP, Pulley M, Quan D, Rezania K, Schellenberg KL, Schultz D, Shoesmith C, Simmons Z, Statland J, Sultan S, Swenson A, Berg LHVD, Vu T, Vucic S, Weiss M, Whyte-Rayson A, Wymer J, Zinman L, Rudnicki SA. PMID: 32969758.
      View in: PubMed   Mentions: 1     Fields:    
    13. Fast skeletal muscle troponin activator CK-2066260 mitigates skeletal muscle weakness independently of the underlying cause. J Cachexia Sarcopenia Muscle. 2020 Dec; 11(6):1747-1757. Cheng AJ, Ström J, Hwee DT, Malik FI, Westerblad H. PMID: 32954682.
      View in: PubMed   Mentions: 1     Fields:    
    14. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF. JACC Heart Fail. 2020 04; 8(4):329-340. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Legg JC, Büchele G, Varin C, Kurtz CE, Malik FI, Honarpour N. PMID: 32035892.
      View in: PubMed   Mentions: 5     Fields:    
    15. Functional Characterization of the Intact Diaphragm in a Nebulin-Based Nemaline Myopathy (NM) Model-Effects of the Fast Skeletal Muscle Troponin Activator tirasemtiv. Int J Mol Sci. 2019 Oct 10; 20(20). Lee EJ, Kolb J, Hwee DT, Malik FI, Granzier HL. PMID: 31658633.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    16. Fast skeletal muscle troponin activator CK-2066260 increases fatigue resistance by reducing the energetic cost of muscle contraction. J Physiol. 2019 09; 597(17):4615-4625. Cheng AJ, Hwee DT, Kim LH, Durham N, Yang HT, Hinken AC, Kennedy AR, Terjung RL, Jasper JR, Malik FI, Westerblad H. PMID: 31246276.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    17. A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019; 0(0):1-11. Shefner JM, Cudkowicz ME, Hardiman O, Cockcroft BM, Lee JH, Malik FI, Meng L, Rudnicki SA, Wolff AA, Andrews JA. PMID: 31081694.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    18. Discovery of Tirasemtiv, the First Direct Fast Skeletal Muscle Troponin Activator. ACS Med Chem Lett. 2018 Apr 12; 9(4):354-358. Collibee SE, Bergnes G, Muci A, Browne WF, Garard M, Hinken AC, Russell AJ, Suehiro I, Hartman J, Kawas R, Lu PP, Lee KH, Marquez D, Tomlinson M, Xu D, Kennedy A, Hwee D, Schaletzky J, Leung K, Malik FI, Morgans DJ, Morgan BP. PMID: 29670700.
      View in: PubMed   Mentions:
    19. VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2018 05; 19(3-4):259-266. Andrews JA, Cudkowicz ME, Hardiman O, Meng L, Bian A, Lee J, Wolff AA, Malik FI, Shefner JM. PMID: 29402141.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    20. Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory. J Am Coll Cardiol. 2018 01 30; 71(4):443-453. O'Connor CM, Psotka MA, Fiuzat M, Lindenfeld J, Abraham WT, Bristow MR, Canos D, Harrington RA, Hillebrenner M, Jessup M, Malik FI, Solomon SD, Stockbridge N, Tcheng JE, Unger EF, Whellan DJ, Zuckerman B, Califf RM. PMID: 29389362.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    21. Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis. JAMA Neurol. 2018 01 01; 75(1):58-64. Andrews JA, Meng L, Kulke SF, Rudnicki SA, Wolff AA, Bozik ME, Malik FI, Shefner JM. PMID: 29181534.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    22. CK-2127107 amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve. 2018 05; 57(5):729-734. Andrews JA, Miller TM, Vijayakumar V, Stoltz R, James JK, Meng L, Wolff AA, Malik FI. PMID: 29150952.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
    23. Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil. Nat Commun. 2017 08 04; 8(1):190. Planelles-Herrero VJ, Hartman JJ, Robert-Paganin J, Malik FI, Houdusse A. PMID: 28775348.
      View in: PubMed   Mentions: 22     Fields:    Translation:AnimalsCells
    24. Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. Cardiovasc Drugs Ther. 2017 Aug; 31(4):445-458. Povsic TJ, Scott R, Mahaffey KW, Blaustein R, Edelberg JM, Lefkowitz MP, Solomon SD, Fox JC, Healy KE, Khakoo AY, Losordo DW, Malik FI, Monia BP, Montgomery RL, Riesmeyer J, Schwartz GG, Zelenkofske SL, Wu JC, Wasserman SM, Roe MT. PMID: 28735360.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    25. New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. Eur J Heart Fail. 2017 06; 19(6):718-727. Cowie MR, Filippatos GS, Alonso Garcia MLA, Anker SD, Baczynska A, Bloomfield DM, Borentain M, Bruins Slot K, Cronin M, Doevendans PA, El-Gazayerly A, Gimpelewicz C, Honarpour N, Janmohamed S, Janssen H, Kim AM, Lautsch D, Laws I, Lefkowitz M, Lopez-Sendon J, Lyon AR, Malik FI, McMurray JJV, Metra M, Figueroa Perez S, Pfeffer MA, Pocock SJ, Ponikowski P, Prasad K, Richard-Lordereau I, Roessig L, Rosano GMC, Sherman W, Stough WG, Swedberg K, Tyl B, Zannad F, Boulton C, De Graeff P. PMID: 28345190.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    26. The Ca2+ sensitizer CK-2066260 increases myofibrillar Ca2+ sensitivity and submaximal force selectively in fast skeletal muscle. J Physiol. 2017 03 01; 595(5):1657-1670. Hwee DT, Cheng AJ, Hartman JJ, Hinken AC, Lee K, Durham N, Russell AJ, Malik FI, Westerblad H, Jasper JR. PMID: 27869319.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    27. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 2016 12 10; 388(10062):2895-2903. Teerlink JR, Felker GM, McMurray JJ, Solomon SD, Adams KF, Cleland JG, Ezekowitz JA, Goudev A, Macdonald P, Metra M, Mitrovic V, Ponikowski P, Serpytis P, Spinar J, Tomcsányi J, Vandekerckhove HJ, Voors AA, Monsalvo ML, Johnston J, Malik FI, Honarpour N, . PMID: 27914656.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    28. Highly selective inhibition of myosin motors provides the basis of potential therapeutic application. Proc Natl Acad Sci U S A. 2016 11 22; 113(47):E7448-E7455. Sirigu S, Hartman JJ, Planelles-Herrero VJ, Ropars V, Clancy S, Wang X, Chuang G, Qian X, Lu PP, Barrett E, Rudolph K, Royer C, Morgan BP, Stura EA, Malik FI, Houdusse AM. PMID: 27815532.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    29. Incorporating development of a patient-reported outcome instrument in a clinical drug development program: examples from a heart failure program. Health Qual Life Outcomes. 2016 Sep 15; 14(1):131. Wiklund I, Anatchkova M, Oko-Osi H, von Maltzahn R, Chau D, Malik FI, Patrick DL, Spertus J, Teerlink JR. PMID: 27629389.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    30. Patient-Reported Outcomes in Chronic Heart Failure: Applicability for Regulatory Approval. JACC Heart Fail. 2016 10; 4(10):791-804. Psotka MA, von Maltzahn R, Anatchkova M, Agodoa I, Chau D, Malik FI, Patrick DL, Spertus JA, Wiklund I, Teerlink JR. PMID: 27395351.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic Health
    31. Reduced force of diaphragm muscle fibers in patients with chronic thromboembolic pulmonary hypertension. . 2016 07 01; 311(1):L20-8. Manders E, Bonta PI, Kloek JJ, Symersky P, Bogaard HJ, Hooijman PE, Jasper JR, Malik FI, Stienen GJ, Vonk-Noordegraaf A, de Man FS, Ottenheijm CA. PMID: 27190061.
      View in: PubMed   Mentions:
    32. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. J Am Coll Cardiol. 2016 Mar 29; 67(12):1444-1455. Teerlink JR, Felker GM, McMurray JJV, Ponikowski P, Metra M, Filippatos GS, Ezekowitz JA, Dickstein K, Cleland JGF, Kim JB, Lei L, Knusel B, Wolff AA, Malik FI, Wasserman SM, . PMID: 27012405.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    33. Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. Int J Clin Pharmacol Ther. 2016 Mar; 54(3):217-27. Palaparthy R, Banfield C, Alvarez P, Yan L, Smith B, Johnson J, Monsalvo ML, Malik F. PMID: 26709596.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    34. Letter by Teerlink et al Regarding Article, "Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity". Circ Heart Fail. 2015 Nov; 8(6):1141. Teerlink JR, Malik FI, Kass DA. PMID: 26578671.
      View in: PubMed   Mentions: 3     Fields:    Translation:Animals
    35. Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure. J Clin Pharmacol. 2015 Nov; 55(11):1236-47. Vu T, Ma P, Xiao JJ, Wang YM, Malik FI, Chow AT. PMID: 25951506.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    36. High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS). Leukemia. 2015 Sep; 29(9):1928-38. Mohamedali AM, Gäken J, Ahmed M, Malik F, Smith AE, Best S, Mian S, Gaymes T, Ireland R, Kulasekararaj AG, Mufti GJ. PMID: 25943179.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    37. A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis. Neurotherapeutics. 2015 Apr; 12(2):455-60. Sanders DB, Rosenfeld J, Dimachkie MM, Meng L, Malik FI, . PMID: 25742919.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    38. The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure. J Pharmacol Exp Ther. 2015 Apr; 353(1):159-68. Hwee DT, Kennedy AR, Hartman JJ, Ryans J, Durham N, Malik FI, Jasper JR. PMID: 25678535.
      View in: PubMed   Mentions: 16     Fields:    Translation:AnimalsCells
    39. Tirasemtiv amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve. 2014 Dec; 50(6):925-31. Hansen R, Saikali KG, Chou W, Russell AJ, Chen MM, Vijayakumar V, Stoltz RR, Baudry S, Enoka RM, Morgans DJ, Wolff AA, Malik FI. PMID: 24634285.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    40. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. JACC Heart Fail. 2015 Jan; 3(1):22-29. Greenberg BH, Chou W, Saikali KG, Escandón R, Lee JH, Chen MM, Treshkur T, Megreladze I, Wasserman SM, Eisenberg P, Malik FI, Wolff AA, Shaburishvili T. PMID: 25453536.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    41. Effect of tirasemtiv, a selective activator of the fast skeletal muscle troponin complex, in patients with peripheral artery disease. Vasc Med. 2014 Aug; 19(4):297-306. Bauer TA, Wolff AA, Hirsch AT, Meng LL, Rogers K, Malik FI, Hiatt WR. PMID: 24872402.
      View in: PubMed   Mentions: 1     Fields:    
    42. Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model. PLoS One. 2014; 9(5):e96921. Hwee DT, Kennedy A, Ryans J, Russell AJ, Jia Z, Hinken AC, Morgans DJ, Malik FI, Jasper JR. PMID: 24805850.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    43. Novel drug mechanisms in development for heart failure. Pflugers Arch. 2014 Jun; 466(6):1219-25. Khodjaev SD, Teerlink JR, Malik FI. PMID: 24793049.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    44. Diaphragm fiber strength is reduced in critically ill patients and restored by a troponin activator. Am J Respir Crit Care Med. 2014 Apr 01; 189(7):863-5. Hooijman PE, Beishuizen A, de Waard MC, de Man FS, Vermeijden JW, Steenvoorde P, Bouwman RA, Lommen W, van Hees HW, Heunks LM, Dickhoff C, van der Peet DL, Girbes AR, Jasper JR, Malik FI, Stienen GJ, Hartemink KJ, Paul MA, Ottenheijm CA. PMID: 24684359.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    45. Fast skeletal muscle troponin activator in the dy2J muscular dystrophy model. Muscle Nerve. 2013 Aug; 48(2):279-85. Miciak JJ, Warsing LC, Tibbs ME, Jasper JR, Jampel SB, Malik FI, Tankersley C, Wagner KR. PMID: 23512724.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    46. Deleting exon 55 from the nebulin gene induces severe muscle weakness in a mouse model for nemaline myopathy. Brain. 2013 Jun; 136(Pt 6):1718-31. Ottenheijm CA, Buck D, de Winter JM, Ferrara C, Piroddi N, Tesi C, Jasper JR, Malik FI, Meng H, Stienen GJ, Beggs AH, Labeit S, Poggesi C, Lawlor MW, Granzier H. PMID: 23715096.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimals
    47. Troponin activator augments muscle force in nemaline myopathy patients with nebulin mutations. J Med Genet. 2013 Jun; 50(6):383-92. de Winter JM, Buck D, Hidalgo C, Jasper JR, Malik FI, Clarke NF, Stienen GJ, Lawlor MW, Beggs AH, Ottenheijm CA, Granzier H. PMID: 23572184.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    48. Fast skeletal muscle troponin activation increases force of mouse fast skeletal muscle and ameliorates weakness due to nebulin-deficiency. PLoS One. 2013; 8(2):e55861. Lee EJ, De Winter JM, Buck D, Jasper JR, Malik FI, Labeit S, Ottenheijm CA, Granzier H. PMID: 23437068.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    49. Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012 Sep; 13(5):430-8. Shefner J, Cedarbaum JM, Cudkowicz ME, Maragakis N, Lee J, Jones D, Watson ML, Mahoney K, Chen M, Saikali K, Mao J, Russell AJ, Hansen RL, Malik F, Wolff AA, . PMID: 22591195.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    50. Smooth muscle myosin inhibition: a novel therapeutic approach for pulmonary hypertension. PLoS One. 2012; 7(5):e36302. Ho D, Chen L, Zhao X, Durham N, Pannirselvam M, Vatner DE, Morgans DJ, Malik FI, Vatner SF, Shen YT. PMID: 22563487.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    51. Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med. 2012 Feb 19; 18(3):452-5. Russell AJ, Hartman JJ, Hinken AC, Muci AR, Kawas R, Driscoll L, Godinez G, Lee KH, Marquez D, Browne WF, Chen MM, Clarke D, Collibee SE, Garard M, Hansen R, Jia Z, Lu PP, Rodriguez H, Saikali KG, Schaletzky J, Vijayakumar V, Albertus DL, Claflin DR, Morgans DJ, Morgan BP, Malik FI. PMID: 22344294.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansAnimalsCells
    52. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet. 2011 Aug 20; 378(9792):667-75. Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Escandon RD, Elliott L, Bee R, Habibzadeh MR, Goldman JH, Schiller NB, Malik FI, Wolff AA. PMID: 21856480.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    53. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 2011 Aug 20; 378(9792):676-83. Cleland JG, Teerlink JR, Senior R, Nifontov EM, Mc Murray JJ, Lang CC, Tsyrlin VA, Greenberg BH, Mayet J, Francis DP, Shaburishvili T, Monaghan M, Saltzberg M, Neyses L, Wasserman SM, Lee JH, Saikali KG, Clarke CP, Goldman JH, Wolff AA, Malik FI. PMID: 21856481.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCTClinical Trials
    54. Inhibition of smooth muscle myosin as a novel therapeutic target for hypertension. J Pharmacol Exp Ther. 2011 Oct; 339(1):307-12. Zhao X, Ho D, Abarzúa P, Dhar SK, Wang X, Jia Z, Pannirselvam M, Morgans DJ, Malik FI, Vatner SF. PMID: 21784887.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    55. Cardiac myosin activation part 1: from concept to clinic. J Mol Cell Cardiol. 2011 Oct; 51(4):454-61. Malik FI, Morgan BP. PMID: 21616079.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimals
    56. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011 Mar 18; 331(6023):1439-43. Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, Anderson RL, Sueoka SH, Lee KH, Finer JT, Sakowicz R, Baliga R, Cox DR, Garard M, Godinez G, Kawas R, Kraynack E, Lenzi D, Lu PP, Muci A, Niu C, Qian X, Pierce DW, Pokrovskii M, Suehiro I, Sylvester S, Tochimoto T, Valdez C, Wang W, Katori T, Kass DA, Shen YT, Vatner SF, Morgans DJ. PMID: 21415352.
      View in: PubMed   Mentions: 161     Fields:    Translation:AnimalsCells
    57. Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin. ACS Med Chem Lett. 2010 Dec 09; 1(9):472-7. Morgan BP, Muci A, Lu PP, Qian X, Tochimoto T, Smith WW, Garard M, Kraynack E, Collibee S, Suehiro I, Tomasi A, Valdez SC, Wang W, Jiang H, Hartman J, Rodriguez HM, Kawas R, Sylvester S, Elias KA, Godinez G, Lee K, Anderson R, Sueoka S, Xu D, Wang Z, Djordjevic N, Malik FI, Morgans DJ. PMID: 24900233.
      View in: PubMed   Mentions:
    58. Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail. 2010 Jul; 3(4):522-7. Shen YT, Malik FI, Zhao X, Depre C, Dhar SK, Abarzúa P, Morgans DJ, Vatner SF. PMID: 20498236.
      View in: PubMed   Mentions: 45     Fields:    Translation:Animals
    59. Dobutamine-atropine stress echocardiography for the detection of coronary artery disease in patients with left ventricular hypertrophy. Importance of chamber size and systolic wall stress. Circulation. 2000 Jan 25; 101(3):258-63. Smart SC, Knickelbine T, Malik F, Sagar KB. PMID: 10645921.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    60. Polymorphisms in the umuDC region of Escherichia species. J Bacteriol. 1988 Apr; 170(4):1610-6. Sedgwick SG, Robson M, Malik F. PMID: 2895099.
      View in: PubMed   Mentions: 8     Fields:    Translation:Cells
    Fady's Networks
    Concepts (246)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (5)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑